Figure 4
From: Serum fibronectin distinguishes the early stages of hepatocellular carcinoma
ROC curve of AFP, FN1, and AFP + FN1 in LC vs. HCC and HCC vs. Recovery by ELISA. The final target, FN1, was evaluated by ELISA in 60 independent serum samples (20 LC, 20 HCC, and 20 Recovery). The panel that was developed from AFP and FN1 enhanced the performance of the individual markers in (A) LC vs. HCC and (B) HCC vs. Recovery. AFP and FN1 distinguished HCC from LC patients with high AUROC values, but both were less effective in HCC vs. Recovery. The 2-marker panel of AFP and FN1 increased the detection rate of HCC from recovered patients. Also, the ROC curves for AFP, FN1, and AFP + FN1 were drawn only for the normal range of AFP (<20 ng/mL) patients. (C) LC vs. HCC and (D) HCC vs. Recovery. The AUROC values in each group comparison are shown at the bottom corner of the graph. As expected, AFP alone could not diagnose HCC from LC or Recovery, but FN1 improved the AUROC value by more than 0.3. Adding AFP to FN1 increased the likelihood of differentiating HCC from other benign states.
